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Introduction
Recurrent respiratory papillomatosis (RRP) is the most
common benign neoplasm of the larynx in children. The
causative agent is now known to be human papillomavirus
(HPV) types 6 and 11.1–6 The papilloma may cover the
aerodigestive tract, but often involves the glottis. As the name
denotes, eradicating this disease is difficult because it is
recurrent and at times aggressive. The initial symptoms are
hoarseness or abnormal cry. Other symptoms include stridor,
aphonia and respiratory distress. Sometimes, tracheostomy
may be required in patients who have obstructed airway.
However, the disruption of the mucus blanket that occurs
after tracheostomy may also be a factor in the often explosive
increase in tracheal papillomas.7 Two forms of RRP have
been described: juvenile onset (JORRP) and adult onset
(AORRP).1–2 If the age of onset is 12 years or below, the disease
is classified as JORRP.1–2 Patients with JORRP usually present
between the ages of 2 and 5 years. JORRP presents as multiple
lesions that are unpredictable in their response to treatment
and tend to have a high rate of recurrence. However, adult
papilloma can be aggressive and notoriously recurrent too.
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Recurrent Respiratory Papillomatosis
The aim of this paper is to review the current local pattern of
the disease in our Malaysian population.
Patients and methods
We studied the records of 10 patients treated for RRP between
January 1996 and December 2001 at the Department of
Otorhinolaryngology, Universiti Kebangsaan Malaysia, Kuala
Lumpur. One has been a patient at our institution since 1986.
The patients’ ethnicity, age, sex, clinical presentation, sites
of involvement and form of RRP (juvenile or adult onset)
were reviewed. Treatments and their outcomes were also
documented. Patients were divided into two groups based on
age of onset of RRP: JORRP and AORRP.
Results
The male-to-female ratio was 1:1. The mean age of the patients
was 22 years (range, 3.5–65 years). Of the six patients diagnosed
with JORRP, all were delivered vaginally and four (66%) were
firstborn children. Maternal age ranged from 23 to 30 years.
Three patients were Malay, two Chinese and one Indian (Table
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1). In the AORRP group, three patients were Chinese and one
was German (Table 2). In total, half (50%) of the patients were
Chinese.
Clinical symptoms
Hoarseness was the most common symptom (90%) (Tables 1
and 2). Less common symptoms included cough (30%), stridor
(30%) and aphonia (10%).
Sites of involvement
All of the patients had glottic RRP (Tables 1 and 2). Two had
multiple sites of involvement. One patient (Patient 6) has
undergone treatment since 1986; he presented with aphonia
and had glottic, subglottic, tracheal, bronchus and pulmonary
involvement. Another patient had arytenoid, glottic, subglottic
and oesophageal orifice involvement (Patient 1).
Analysis of differences between AORRP and JORRP
All of the AORRP patients were male, while only one of the
JORRP patients was male. The average age at presentation was
2 years (range, 3.5–16 years) in the JORRP group and 42 years
(range, 26–65 years) in the AORRP group.
The average number of past procedures (suspension
microlaryngoscopy with CO2 laser ablation) performed in
JORRP patients was five compared to 3.5 in AORRP. These
results exclude Patient 6, who had more than 60 procedures to
debulk the papilloma between 1986 and 2001.
Two JORRP patients had previously presented to our
department with subglottic papilloma with multiple sites of
involvement. One of them, Patient 6, was diagnosed with RRP
in 1986, when he presented to our department with a history
of aphonia. He underwent a tracheostomy for airway protection
in June 1987. Subsequently, bronchus involvement was noted
Table 2. Summary of patients with adult-onset recurrent respiratory papillomatosis
Patient Age Race Sex Symptom Site Procedures Adjuvant Tracheostomy Resolution
number  (years) (n) therapy
7 26 Chinese M Hoarseness Glottic 1 None None Defaulted
follow- up
8 34 Chinese M Hoarseness Glottic 5 None None Under
follow-up
9 50 German M Hoarseness Glottic 8 None None Under
follow-up
10 65 Chinese M Hoarseness Glottic 1 None None Under
follow-up
Table 1. Characteristics of patients with juvenile-onset recurrent respiratory papillomatosis
Patient Age Race Sex Symptom Site Procedures Adjuvant Tracheostomy Resolution
number  (years)  (n) therapy
1 3.5 Malay F Hoarseness, cough, Glottic, subglottic, 3 None None Under
stridor arytenoid, follow-up
oesophageal orifice
2 8 Indian F Hoarseness Glottic 7 None None Under
follow-up
3 9 Chinese F Hoarseness Glottic 8 None None Discharged
with good
voice
4 9 Malay F Hoarseness Glottic 3 None None Discharged
with good
voice
5 9 Malay F Hoarseness, cough Glottic 5 α-Interferon None Under
follow-up
6 16 Chinese M Aphonia, stridor, Glottic, subglottic, > 60 α-Interferon 1 in Under
cough bronchus, trachea,  since 1987 follow-up
lung parenchyma 1986
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Discussion
RRP remains a frustrating disease to treat and has potentially
morbid consequences because of its involvement of the airway
and the frequency of recurrence. RRP is caused by HPV types
6 and 11, which also cause genital condylomas.1–6 However,
the precise mechanisms of transmission, pathogenesis and
immune response to HPV remain unclear.
The common symptoms of RRP include progressive
hoarseness, stridor and respiratory distress. Less commonly,
chronic cough, recurrent pneumonia, failure to thrive,
dyspnoea and dysphagia may be the presenting symptoms.1,2
In our study, nine patients had progressive hoarseness as a
presenting symptom. Three patients had concomitant cough
and stridor. The youngest RRP patient in the literature
presented at 1 day of age and the oldest at 84 years.4 Our oldest
patient is 65 years old and presented with hoarseness for 1 year
prior to treatment at our institution; our youngest patient
presented with aphonia at the age of 1 year.
Although RRP can be found anywhere in the aerodigestive
tract, there appears to be a predilection for areas where there is
a junction of squamous and ciliary epithelium. The
predominant sites of disease in RRP are the limen vestibuli, the
nasopharyngeal surface of the soft palate, the midzone of the
laryngeal surface of the epiglottis, the upper and lower margins
of the ventricle, the undersurface of vocal folds, the carina and
bronchial spurs.8 Dedo and Yu found that, in 227 (93%) of
their 244 patients with RRP over the larynx, 29 cases occurred
at the trachea and only three (1%) in the lung parenchyma.9 In
our study, all patients had involvement of the larynx.
In our patient who underwent a tracheostomy in 1987, the
papilloma spread into the trachea, bronchus and lung
parenchyma. Lung parenchyma and distal trachea spread
have been reported to occur in 5% of patients with RRP.4
Kashima et al noted that 15% of patients with JORRP require
tracheostomy for airway management.8 A tracheostomy may
spread the papilloma distally because of mucosal abrasion,
but sometimes it is necessary to prevent airway compro-
mise.9,10 Cole et al concluded from their review of 12 patients
with tracheostomy that, whenever possible, tracheostomy
should be avoided in patients with RRP.11 When tracheostomy
is unavoidable, however, every effort should be made to keep
the duration of cannulation as short as possible. It may be
coincidental, but in our series, the only patient who underwent
a tracheostomy also has the longest standing disease. A study
by Shapiro et al noted that patients requiring tracheostomy
may harbour a more aggressive form of disease, requiring
in April 1988, for which he had a 6-month trial of α-interferon
therapy but without any improvement; recurrence was noted
after the treatment. From 1986 to December 2001, he had
more than 60 procedures to debulk the papilloma. Thorax
computed tomography (CT) performed in August 2001 showed
involvement of the right and left lungs, in both lower lobes.
CT-guided biopsy showed benign squamous cells with few
dysplastic cells and no malignant cells. With 15 years of follow-
up and a history of 60 procedures, he is obviously the patient
with the most fulminant disease.
Patient 5 was also given α-interferon therapy after she had
four debulking procedures performed within 1 year. This
patient also had recurrence after completing the interferon
therapy.
Patient 1 had papilloma involving the left vocal cord,
anterior commissure, arytenoid, oesophageal orifice and
subglottic area. She initially presented with hoarseness, cough
and stridor.
Patients 1 and 6 are still undergoing periodic laser ablation
of their papillomas.
Resolution
Two patients (20%) had spontaneous remission after multiple
procedures to debulk the papilloma with CO2 laser. Patient 3,
who had RRP for 5 years and had undergone eight procedures
before remission was noted at 9 years of age, was discharged
well with good voice. Patient 4, who had RRP for 8 years and
underwent three procedures, was discharged well with good
voice at 9 years of age. Although no complete remissions were
noted in the AORRP group, this may have been due to the
short follow-up period. So far, all AORRP patients are requiring
less frequent procedures and the rates of growth of the
papillomas have slowed.
Table 3. Results of comparative analysis of patients with juvenile-
onset versus adult-onset recurrent respiratory papillomatosis
 Juvenile Adult
Sex 5F, 1M 4M, 0F
Onset age* 2 42
Number of procedures* 5 3.5
Early site no.* 2 1
Subglottic involvement (n) 2 0
Distal spread 2 0
Resolution 2 0
Tracheostomy 1 0
Interferon therapy 2 0
*Mean.
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more surgical procedures and causing more obstructive
disease,12 such as Patient 6 in our series.
RRP may have its clinical onset during either childhood
or adulthood. Two distinct forms are generally recognized:
a juvenile or aggressive form and an adult or less aggress-
ive form. The aggressive form, although most prevalent in
children, also occurs in adults. The two forms are histologically
identical.5 Aggressive disease has been defined as that requiring
at least 10 total procedures, with three or more procedures
within 1 year, and spread of the disease to the subglottic
region.5
In our JORRP group, three patients were Malay, two were
Chinese and one was Indian. Among the AORRP group, there
were three Chinese and one German patient. Although the
numbers were small, they suggest that RRP may occur more
commonly in Chinese. This is meaningful because the majority
of the population in our country is Malay (60%), not Chinese
(20%).
JORRP was more common in females (ratio 5:1) while all
AORRP patients were male. This is consistent with a 1997
review by Evans, which reported female preponderance in
JORRP in contrast with AORRP, where the reverse is true.7 The
average number of procedures done was higher in JORRP in
our series. Early subglottic involvement was noted in two
patients in the juvenile group. These two patients also had
multiple sites of involvement and were noted to have papilloma
at the ages of 1 and 3.5 years old, respectively. This is consistent
with a 1994 study by Doyle et al, where early subglottic and
multi-site involvement were more common in the aggressive
form of RRP.5
The clinical triad of a firstborn child delivered vaginally to
a young teenage mother has been linked to JORRP.13 All of our
patients were born vaginally, but only four patients had two
components of the triad. Remission of RRP can take place at
any age and any time. Two (20%) of our JORRP patients had
remission at the age of 9 years. The chances of remission are
greater between the ages of 6 and 10 years.7 However, relapse
may occur at any time and for no apparent reason.7
The aim of RRP treatment is to achieve a lesion-free state
and maintenance of adequate airway by surgical excision. It is
the policy of our institution that patients with massive RRP
are treated with CO2 laser ablation after removal of the larger
papillomas using microforceps under suspension micro-
laryngoscopy. The CO2 laser is the most versatile laser for RRP
ablation because it can perform both coagulation and cutting
functions, and can be operated in continuous or pulsed modes.
The CO2 laser used with suspension laryngoscopy permits
precise, thorough and an essentially bloodless papilloma
excision. In addition, vocal quality is better preserved with
the CO2 laser compared with cup forceps removal of vocal
cords because the mucous membrane appears to have less
scarring.9 Dedo and Yu found that frequent and meticulously
performed CO2 laser excision achieved improvement and
clinical “cure” (defined as no papilloma for 5 years after last
removal) in 17% of their 244 patients.9 Stern et al advocated
spontaneous respiration anaesthesia for complete unimpeded
access to the larynx, safe airway with adequate ventilation, and
reduction in the risk of combustion in the application of CO2
laser energy.14 We use a metal endotracheal tube in a paralyzed
patient as we prefer absolute absence of movement during the
laser procedure. We also use tubeless anaesthesia when there is
papilloma at the posterior commissure, which is “hidden” by
the endotracheal tube. If the papilloma involves subglottic
and upper tracheal tissue, we use a subglottiscope for direct
visualization and laser ablate the lesion. We sometimes use
cupped forceps to remove papillomas in these regions where
visualization and access are limited by distorted anatomy.
Potential complications of this disease and its treatment
include stenosis, webbing, vocal cord scarring, granulation
tissue formation, trachea perforation, tracheo-oesophageal
fistula, respiratory arrest, bronchitis, pneumonia, pneumo-
thorax, haemorrhage and death.5,9,10 None of our patients
developed these complications. About 10% of patients with
RRP require some form of adjuvant therapy. There are
numerous adjuvant therapies reported in the literature,
including cidofovir intralesional injections, photodynamic
therapy, argon plasma coagulation, pulsed dye laser and indole-
3-carbinol (I3C).1,15–19
The accepted criteria for adjuvant therapy include the need
for four procedures per year, distal multi-site spread of the
disease, and rapid regrowth of papilloma with airway
compromise.1 The most common adjuvant therapy is
α-interferon.4 It appears to modulate host immune response
by increasing production of protein kinase and endonu-
clease.1,2 Therapy is initiated at 5 million units/m2 body surface
area administered by daily subcutaneous injection for 28 days,
and then 3 days per week for at least a 6-month trial.1,2 Side
effects include flu-like symptoms, elevation of hepatic enzymes,
renal insufficiency, anorexia, seizure, gastrointestinal distress
and transient numbness.1 Two of our patients showed no
improvement in their disease after the treatment. This is
consistent with the findings of Healy et al which showed
unaffected growth of papilloma after an initial 6 months of
interferon use.20
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I3C, a derivative of cruciferous vegetables, has been shown
to alter the growth of papilloma in mice by altering oestrogen
metabolism.21 Rosen et al reported that, of 18 children who were
treated with pure I3C, only six showed complete response.22
Adverse effects include dizziness, headaches, unsteady gait,
goitrogenicity and decreased bone density.23
Photodynamic therapy involves the administration of a
photosensitizing agent, dihaematoporphyrin, which is
concentrated in rapidly growing tissues. Following
administration of this agent, the lesions are excised with an
argon pump dye laser which preferentially destroys the tissues
that concentrated the dye.17 The main side effect is
photosensitivity, which lasts from weeks to months.1
Nucleoside analogues such as cidofovir inhibit viral
DNA polymerase, which is responsible for the production of
new viral RNA and DNA. Pranksy et al used intralesional
cidofovir in 10 paediatric patients, all with good response.15,16
However, toxicity of intralesional cidofovir has not been fully
established.16
In conclusion, RRP remains a devastating disease with its
recurrent nature and potential for distal spread and airway
obstruction. Thorough patient history and examination are
warranted. Vigilant initial assessment with a rigid endoscope
under suspension laryngoscopy for local and distal involvement
is extremely important to uncover more aggressive disease.
Whenever possible, tracheostomy should be avoided in patients
with RRP. Proper debulking with CO2 laser ablation is the key
to control of the disease, providing adequate airway and
preventing complications from multiple treatment.
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